Stifel Nicolaus Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price target decreased by stock analysts at Stifel Nicolaus from $130.00 to $85.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 16.60% from the stock’s previous close.

TMDX has been the topic of a number of other reports. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Monday, March 16th. Piper Sandler lowered their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC lowered their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $135.00.

TransMedics Group Price Performance

Shares of TMDX opened at $72.90 on Wednesday. TransMedics Group has a 52-week low of $70.00 and a 52-week high of $156.00. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.59 and a current ratio of 6.74. The business’s 50 day moving average price is $114.04 and its two-hundred day moving average price is $125.34. The firm has a market cap of $2.52 billion, a PE ratio of 16.57 and a beta of 2.07.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. During the same period last year, the firm posted $0.70 earnings per share. TransMedics Group’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group will post 2.48 EPS for the current year.

Insider Activity at TransMedics Group

In other news, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Weill sold 3,571 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total value of $524,294.22. Following the sale, the director owned 12,134 shares of the company’s stock, valued at $1,781,513.88. This trade represents a 22.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 16,205 shares of company stock valued at $2,353,002 over the last three months. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently bought and sold shares of TMDX. Royal Bank of Canada grew its holdings in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in TransMedics Group by 13.5% during the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after buying an additional 938 shares in the last quarter. Finally, M&T Bank Corp bought a new stake in TransMedics Group during the second quarter worth $209,000. Institutional investors own 99.67% of the company’s stock.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Several brokers kept bullish ratings despite cutting targets, signaling continued upside if execution improves — Piper Sandler set a new $120 price target (overweight). Article Title
• Positive Sentiment: TD Cowen trimmed its target to $120 but maintained a buy stance, implying significant upside from current levels if growth rebounds. Article Title
• Positive Sentiment: Canaccord lowered its target to $124 and kept a buy rating, showing some brokers view the pullback as a buying opportunity. Article Title
• Positive Sentiment: Needham cut its target to $142 but retained a buy rating, highlighting that some analysts still model strong longer‑term growth for TransMedics. Article Title
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors digging into management commentary on OCS demand, margins and international expansion. Article Title
• Neutral Sentiment: Industry coverage notes growth remains concentrated in OCS demand though execution and margin recovery are key monitorables. Article Title
• Negative Sentiment: Q1 results: revenue grew ~21% but EPS missed materially and margins contracted — the immediate driver of the selloff. Article Title
• Negative Sentiment: Analyst tone weakened: Stifel cut its target sharply to $85 and moved to hold, and Oppenheimer downgraded TMDX to Market Perform — signaling rising skepticism on near‑term execution. Article Title Article Title
• Negative Sentiment: Critical analysis argues the stock still prices near‑perfect execution and that growth levers (CHOPS, OPO conversion, international) are uncertain — a view that supports further downside until evidence of durable margin recovery appears. Article Title

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.